For research use only. Not for therapeutic Use.
Alogliptin（Cat No.:A000935）is an oral antidiabetic medication and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, used to improve glycemic control in type 2 diabetes. By inhibiting DPP-4, alogliptin prolongs the activity of incretin hormones, which increase insulin release and decrease glucagon levels in response to meals, helping to regulate blood glucose levels. With a favorable safety profile, it has a low risk of hypoglycemia and is often well-tolerated. Alogliptin can be used alone or in combination with other antidiabetic agents, supporting more comprehensive diabetes management for improved patient outcomes.
| Catalog Number | A000935 |
| CAS Number | 850649-61-5 |
| Synonyms | YR-322 |
| Molecular Formula | C18H21N5O2 |
| Purity | ≥95% |
| Target | Apoptosis |
| Solubility | >14.8mg/mL in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile |
| InChI | InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1 |
| InChIKey | ZSBOMTDTBDDKMP-OAHLLOKOSA-N |
| SMILES | CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N |
